Abstract
Polyethylene glycol-conjugated (PEG) asparaginase is approved for use in patients who develop allergy to other forms of asparaginase, although its ability to deplete asparagine systemically in patients with hypersensitivity has not been well elucidated. In 53 children with newly diagnosed acute lymphoblastic leukemia, we serially assessed asparagine concentrations in cerebrospinal fluid (CSF) and plasma as well as serum anti-asparaginase antibodies. All patients received native Escherichia coli (Elspar) asparaginase during induction therapy; patients received PEG asparaginase during reinductions when available, and those who developed allergy received Erwinia asparaginase. All eight patients who developed clinical evidence of allergy to asparaginase had anti-asparaginase antibodies. Among patients who had no antibodies, those who received E. coli had lower mean (±s.d.) CSF asparagine (0.29±0.63, n=9) than those who received PEG (0.77±0.82, n=4) (P=0.007). Results were similar for plasma asparagine. There was no situation where asparagine concentrations were more effectively depleted by PEG than by other preparations. None of the five patients who developed thrombosis had an allergy or antibodies to asparaginase at the time of the thrombosis. We conclude that asparagine concentrations were less effectively depleted by PEG than by E. coli asparaginase at the doses commonly used. The risk of thrombosis may be affected by the intensity of asparaginase exposure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pui C-H, Evans WE . Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605–615.
Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218.
Asselin BL, Kurtzberg J . Asparaginase. In: Pui C-H (ed) Treatment of Acute Leukemias. New Directions for Clinical Research. Totowa, NJ: Humana Press, 2003, pp 365–379.
Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell JN et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315: 657–683.
Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893–901.
Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989; 49: 4363–4368.
Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen JH . Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780–1786.
Peterson RG, Hanschumacher RE, Mitchell MS . Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080–1090.
Keating MJ, Holmes R, Lerner S, Ho DH . L-asparaginase and PEG asparaginase-past, present, and future. Leukemia Lymphoma 1993; 10: 153–157.
Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallal L, Tan CC et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25: 253–278.
Woo MH, Hak LJ, Storm MC, Sandlund JR, Ribeiro RC, Rivera GK et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527–1533.
Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B et al. Hypersensitivity reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220–228.
Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084–3091.
Wang B, Hak LJ, Relling MV, Pui C-H, Woo MH, Storm MC . Elisa to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000; 239: 75–83.
Lehmann EL . Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA: Holden-Day, Inc., 1975, 51pp.
Agresti A . An Introduction Categorical Data Analysis. New York, NY: John Wiley & Sons, Inc., 1996, 39pp.
Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG . Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983; 43: 5601–5607.
Ahlke E, Nowak-Gottl U, Schulze-Westhott P, Werber G, Borste H, Wurthwein G et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamics control during induction therapy in children with acute lymphoblastic leukemia. Br J Haematol 1997; 96: 675–681.
Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G et al. Monitoring of asparaginase activity and asparagines levels in children on different asparaginase preparations. Eur J Can 1996; 32A: 1544–1550.
Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR . Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000; 96: 1709–1715.
Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK et al. Hypersensitivity or development of antibodies of asparaginase do not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525–1532.
Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui C-H et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17: 1583–1588.
Avramis VI, Sencer S, Periciou AP, Hather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99: 1986–1994.
Mitchell LG, Sutor AH, Andrew M . Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Throm Hemostasis 1995; 21: 390–401.
Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595–1599.
Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer – Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734–2739.
Nowak-Gottl U, Boos J, Wolff JEA, Erber G, Ahlke E, Pollmann H et al. Influence of two different E. coli asparaginase preparations on coagulation and fibrinolysis: a randomized trial. Fibrinolysis 1994; 8: 66.
Acknowledgements
This work was supported by NCI CA CA21765; by the General Clinical Research Center Grant M01-RR00211; by a Center of Excellence grant from the State of Tennessee; and by the American Lebanese Syrian Associated Charities (ALSAC). C-H Pui is the American Cancer Society FM Kirby Clinical Research Professor. We thank our protocol coinvestigators, clinical staff, research nurses (Sheri Ring, Lisa Walters, Margaret Edwards, Terri Kuehner, and Paula Condy), the patients, and their parents for their participation. We also thank Nancy Kornegay and Carl Panetta for computing assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hak, L., Relling, M., Cheng, C. et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18, 1072–1077 (2004). https://doi.org/10.1038/sj.leu.2403351
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403351
Keywords
This article is cited by
-
Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review
Clinical Reviews in Allergy & Immunology (2022)
-
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase
Cancer Chemotherapy and Pharmacology (2021)
-
Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study
Scientific Reports (2016)
-
Extracellular expression and affinity purification of L-asparaginase from E. chrysanthemi in E. coli
Sustainable Chemical Processes (2014)
-
Semi-permeable coatings fabricated from comb-polymers efficiently protect proteins in vivo
Nature Communications (2014)